Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 81 clinical trials
Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma (I-MAT)

The I-MAT trial is a randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma aiming to explore the efficacy of avelumab as adjuvant

renal function
positron emission tomography
avelumab
18f-fdg
immunomodulator
  • 1 views
  • 03 Jun, 2022
  • 17 locations
Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1 (AVENTIL)

This is a phase 1, dose-escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with avelumab in patients with advanced solid tumors refractory to or progressing

  • 0 views
  • 27 Jul, 2022
  • 1 location
Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)

Phase II Study of Avelumab plus chemotherapy in the peri-operative treatment for patients with resectable Gastric cancer (GC) or Gastroesphageal Junction cancer (GEJC) The addition of

cancer chemotherapy
direct bilirubin
docetaxel
neutrophil count
ct scan
  • 0 views
  • 10 Oct, 2021
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (InCITe)

This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in

measurable disease
liver metastasis
neutrophil count
invasive breast cancer
progesterone
  • 27 views
  • 17 Jun, 2022
  • 4 locations
A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy (AXAGIST)

To assess anti-tumor activity of avelumab in combination with axitinib in patients with unresectable/metastatic GIST after progression on second or third line treatment (after failure on at

measurable disease
imatinib
neutrophil count
metastatic gastrointestinal stromal tumor (gist)
thromboplastin
  • 0 views
  • 25 Feb, 2022
  • 1 location
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

This phase I/II trial studies the best dose and side effects of peposertib and to see how well it works with avelumab and hypofractionated radiation therapy in treating patients with solid

measurable disease
neutrophil count
glomerular filtration rate
anti-cancer agents
antibody therapy
  • 129 views
  • 12 Jul, 2022
  • 3 locations
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

-tumour immune response in patients both as monotherapy and in combination pemetrexed/cisplatin/avelumab (Part B Mesothelioma and NSCLC 1st line), in combination with avelumab (Part B Cutaneous Melanoma

pemetrexed
cancer
  • 2 views
  • 03 Jun, 2022
  • 3 locations
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy

therapy (as mono or combination), when administered as combined with avelumab.

measurable disease
avelumab
  • 6 views
  • 11 Aug, 2022
  • 1 location
Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

This phase II trial studies the effect of avelumab, gemcitabine and carboplatin before surgery compared with surgery alone in treating patients with muscle invasive bladder or upper urinary

  • 0 views
  • 24 Jul, 2022
  • 66 locations
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy

, the disease returns and people need more treatment to keep the cancer from growing. The drug Avelumab could help the immune system fight cancer. Objective To

pd-l1
measurable disease
chemotherapy regimen
progressive disease
avelumab
  • 56 views
  • 12 Aug, 2022
  • 1 location